Many Drug Approval Delays, Denials Could Be Prevented, FDA Study Shows
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency reports preventable deficiencies, including failure to select optimal drug doses and suitable study endpoints, account for many drug rejections, approval delays.